67287-36-9

Usage

Uses

Used in Pharmaceutical Industry:
2-(2-Chloro-3,4-dimethoxyphenyl)ethanamine is used as a reactant for the preparation of 1-aryl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diols. These compounds are potent D-1 dopamine agonists, which have potential applications in the treatment of various neurological and psychiatric disorders, such as Parkinson's disease and schizophrenia. The presence of the chloro and methoxy groups in 2-(2-chloro-3,4-dimethoxyphenyl)ethanamine contributes to the desired pharmacological properties of the resulting benzazepine derivatives, enhancing their efficacy as D-1 dopamine agonists.

InChI:InChI=1/C10H14ClNO2/c1-13-8-4-3-7(5-6-12)9(11)10(8)14-2/h3-4H,5-6,12H2,1-2H3

Upstream product

• 41122-35-4 2-chloro-3,4-dimethoxy-1-(2-nitrovinyl)benzene 
• 7537-07-7 2-(2-chloro-3,4-dimethoxyphenyl)acetonitrile 
• 18268-68-3 5-chloroveratraldehyde 
• 27164-13-2 5-chloro-3,4-dimethoxy-1-(2-nitrovinyl)benzene 
• 121-33-5 vanillin 
• 19463-48-0 5-chlorovanillin 
• 93983-13-2 2-chloro-3,4-dimethoxybenzyl alcohol 
• 37687-57-3 2-chloro-3-hydroxy-4-methoxybenzaldehyde 
• 5417-17-4 2-chloro-3,4-dimethoxybenzaldehyde 
• 93983-14-3 2-chloro-3,4-dimethoxybenzyl chloride 
• 621-59-0 isovanillin 
• 41122-35-4 (E)-2-chloro-3,4-dimethoxy-1-(2-nitrovinyl)benzene 

Downstream Products

• 67287-37-0 N-(2-Hydroxy-2-phenethyl)-N-<2-(2'-chlor-3',4'-dimethoxyphenyl)-ethyl>-amin 
• 67287-62-1 2-[2-(2-Chloro-3,4-dimethoxy-phenyl)-ethylamino]-1-p-tolyl-ethanol 
• 71636-38-9 N-[2-hydroxy-2-(4'-methoxyphenyl)ethyl]-2-(2-chloro-3,4-dimethoxyphenyl)ethylamine 
• 67287-60-9 N-[2-(2-chloro-3,4-dimethoxyphenyl)-ethyl]-2-hydroxy-2-(m-methoxyphenyl)ethylamine 
• 80751-53-7 2-[2-(2-Chloro-3,4-dimethoxy-phenyl)-ethylamino]-1-(3-chloro-phenyl)-ethanol 
• 77969-29-0 2-[2-(2-Chloro-3,4-dimethoxy-phenyl)-ethylamino]-1-o-tolyl-ethanol 
• 77969-37-0 3-(trifluoromethyl)-α-<<(2-chloro-3,4-dimethoxyphenethyl)amino>methyl>benzyl methyl ether 
• 71636-61-8 (+-)-6-chloro-7, 8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine 
• 67227-56-9 fenoldopam 
• 901773-06-6 C₁₉H₂₂ClNO₄ 
• 3217-93-4 N-phenylethylhydroxylamine 
• 102851-70-7 2-chlorodopamine 
• 1429438-68-5 ethyl 2-chloro-3,4-dimethoxyphenylethylcarbamate 
• 1429438-71-0 5-chloro-6,7-bis((4-methoxybenzyl)oxy)-2-(2-(pyrrolidin-1-yl)ethyl)-3,4-dihydroisoquinolin-1(2H)-one 

Relevant academic research and scientific papers

Chemoselective zinc/HCl reduction of halogenated β-nitrostyrenes: Synthesis of halogenated dopamine analogues

A detailed account regarding the synthesis of 2- and 5-halogenated dopamine is given. The key step is a chemoselective reduction of a nitrostyrene by Zn/HCl at 0 °C. These conditions represent a simple, low-cost alternative to reduction by water-sensitive hydride donors and two-step procedures. Under these conditions, aryl fluoride, chloride, and bromide groups are stable. However, iodine undergoes significant reductive dehalogenation.

ANTIBACTERIAL COMPOUNDS

The present Invention relates to cephalosporin antibacterial compounds of Formula (!): corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods for bacterial infections, especially those caused by gram-negative bacteria.

Process for the preparation of Fenoldopam Mesylate

Methods and intermediates for the preparation of Fenoldopam mesylate and intermediates thereof are provided.

Solid oral preparation containing a pyrrolidine derivative with a catechol group

An oral solid preparation comprising an organic acid or its salt and a catechol compound. The catechol compound is, for example, a pyrrolidine derivative having a catechol group of the following general formula (I). It exhibits an improved absorbability in vivo. STR1

6-HALO-3-LOWER ALKYL-7,8-DIHYDROXY-1-PHENYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES

6-Halo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines whose structures have a lower alkyl substituted at the 3 or N-position have potent and often specific anti-Parkinsonism activity by means of their central dopaminergic effect. The lead compound of the series is 6-chloro-3-methyl-1-phenyl-7,8-dihydroxy-2,3,4,5-tetrahydro-1H-3-benzazepin e as the base or its salts such as the hydrochloride, hydrobromide or methane sulfonate.

Substituted 1-alkylthiophenyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds

A group of 1-phenyl-1H-3-benzazepines whose structures are characterized by having a functional thio containing group on the 1-phenyl moiety and which have pronounced peripheral and diminished central dopaminergic activity. This activity is manifested in an anti-hypertensive effect in humans. Particular species of this group include 6-chloro-7,8-dihydroxy-1-p-methylthiophenyl-2,3,4,5-tetrahydro-1H-3-benzazepine and its derivatives which have dopaminergic activity.